Objective: The Afirma GEC (GEC) molecular marker assay was developed for the purpose of improving surgical decision-making with indeterminate fine needle aspiration (FNA) biopsies of thyroid nodules. In this paper, we analyze the performance of the GEC over 27 months in a community hospital-based thyroid surgery practice.
Introduction
Since the landmark report of Kimura et al in 2003 linking the BRAF mutation with papillary thyroid cancer (1), endocrinologists and endocrine surgeons have held great expectations that one day genetic analysis of thyroid fine needle aspiration biopsy specimens might decrease the number of unnecessary surgeries performed for patients with cytologically "indeterminate" thyroid nodules. While the presence of the V600E BRAF mutation proved to be highly predictive of papillary cancer, the fact that 40-60% of patients with a tissue diagnosis of papillary cancer do not carry a BRAF mutation has limited the diagnostic applicability of this genetic test (2) . Researchers have subsequently attempted to identify other genetic mutations and translocations that could predict thyroid cancer. One after another, mutations in RAS and translocations in RET/PTC and PAX8/PPAR gamma have proven to be useful when present in patient cytological samples, but unhelpful for patients whose thyroid cancers do not exhibit known genetic alterations (2) .
In 2010, Chudova et al took a different approach by analyzing the amplified transcriptome (mRNA) of fine needle aspiration biopsy specimens (FNA's) from patients undergoing thyroid surgery, with the intention of developing a gene expression test that could predict benignity. Mathematical analysis led to the development of a 142 gene cDNA Affymetrix cassette (Afirma GEC) capable of separating "benign" from "suspicious" FNA specimens in a small independent cohort of prospectively collected samples. Initial statistical analysis was promising with a "benign" GEC result yielding a negative predictive value (NPV) of 96% (3) . Further testing led to the Alexander et al paper in 2012 that further validated the Afirma GEC in FNA's from 265 patients with cytologically indeterminate nodules, with the authors reporting an overall NPV of 94% in patients with pre-operative negative GEC's (4).
However, negative predictive value has an inverse relationship with the overall prevalence of thyroid cancer in the indeterminate cytology group studied (5). We reasoned that the incidence of thyroid cancer in patient groups with indeterminate thyroid cytology might vary according to geographic region and type of thyroid cancer practice. Therefore, we chose to evaluate our South Florida (Memorial Center for Integrative Endocrine Surgery) Afirma GEC experience over the past 27 months and to calculate our own practice-specific NPV. In addition, we examined cytological and pathological idiosyncrasies in our patient group that might potentially affect GEC performance.
Methods
From 1/2011 through 4/2013, all thyroid FNA cytology specimens from our South Florida endocrine surgery practice were sent to Thyroid Cytopathology Partners (TCP) of Austin, Texas along with an Afirma washout specimen of RNA preserved in FNA-protect. Patients were selected for thyroid nodule FNA based on American Association of Clinical Endocrinologists (AACE) Thyroid Nodule Guideline criteria, and all biopsies were performed under General Electric Logiq E9 or S8 ultrasound guidance using a parallel-to-the-beam technique. Each nodule was sampled with three to five 25 gauge needle passes and slides were fixed in 95% ethanol and dried for transport. Each needle's contents were washed into FNA-protect after initial use for slide creation. After cytologic characterization at TCP, FNA-protect washes from all of our 58 indeterminate biopsies were sent to Veracyte, Inc. in South San Francisco, California for Afirma GEC testing.
The nomenclature for indeterminate FNA result classification is divided into two groups including (1) atypia of undetermined significance or follicular lesion of undetermined significance (AUS-FLUS), either follicular or Hurthle Cell predominant, and (2) follicular neoplasm (FN), either follicular or Hurthle Cell predominant.
Throughout the text of this report, the terms Hurthle Cell and oncocyte are used interchangeably.
FNA's read as "suspicious for malignancy" were not included in our indeterminate FNA analysis because Veracyte has excluded them from Afirma GEC testing since the summer of 2012. Over the course of the study, only four FNA's were interpreted as "suspicious for malignancy" by Thyroid Cytology Partners and all proved to be cancers at surgery. Negative predictive value was estimated using the standard equation for negative predictive value and our data was presented using a conventional 2 x 2 table with pre-surgical Afirma GEC results, benign and suspicious, plotted versus clinically significant surgical pathologic diagnoses, benign and malignant (Table 1) (5). Four subcentimeter papillary microcarcinomas, contralateral from the actual nodule biopsied, were not considered to be clinically significant malignancies.
Results

Nodule and Patient Characteristics
We performed 645 FNA's in 519 patients over 27 months.
The 58 biopsies read as indeterminate by Thyroid Cytopathology Partners ranged in size from 0.6 to 5 cm, averaging 1.5 cm. We sampled six sub-centimeter nodules that were found to have indeterminate cytology. These sub-centimeter nodules were biopsied because of suspicious ultrasound findings or strong family histories of thyroid cancer and constituted only 10.3% of the entire indeterminate group.
The 58 indeterminate nodules represented 9% of the total FNA's sent to Thyroid Cytopathology Partners over the time frame of the study. 36 of these indeterminate biopsies were classified as suspicious by Afirma GEC (62%), 20 were characterized as GEC benign (34%) and 2 were determined to be inadequate due to low mRNA content (3%).
The 58 patients whose thyroid FNA's were sent for Afirma GEC analysis averaged 53 years of age and were predominantly female (43 females in the group or 76%). The ethnicity of the group was largely Caucasian (67%), with Hispanic (16%), African American (14%) and Asian (3%) minority representation.
Surgical Results
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Of the 36 suspicious GEC patients, 30 (83%) underwent thyroidectomy. Twentyone of the 30 had malignant final pathology. Four of the 21 patients with malignant final pathologic diagnoses had isolated co-incidental sub-centimeter papillary microcarcinomas in the contralateral thyroid lobe from their biopsied Afirma GEC suspicious nodules (the false positive GEC lesions ranged from 1.0 to 1.6 cm in size). Of the GEC suspicious patients who did not undergo surgery, 5 refused surgical intervention and one is in the process of completing chemotherapy for breast cancer prior to her thyroidectomy.
Of the 20 benign GEC patients, 5 underwent thyroid surgery and 2 were discovered to have malignancies. The false negative results in these two malignant thyroid nodules were likely due to sampling error, with the first nodule being a 0.64 cm papillary cancer, and the second a 2.8 cm cystic papillary cancer. Surgery was performed in the first patient because a frankly malignant aspirate in the contralateral thyroid lobe and in the second case because of a positive family history and recent nodule growth. All GEC benign patients were encouraged to return for yearly follow-up with sequential neck ultrasound evaluation.
One of the two patients with non-diagnostic GEC's (inadequate RNA) underwent lobectomy for a benign thyroid cyst.
Calculation of NPV
In an effort to construct a "best case scenario" for calculation of the negative predictive value of the Afirma GEC in our practice, we excluded the four incidental and remote papillary microcarcinomas and assumed a minimum cancer prevalence of 17 cases in the Afirma suspicious group and 2 cases in the Afirma benign group for a total of 19 cancers in 58 patients. Thus our minimum cancer prevalence in the indeterminate FNA group was 33% (Table 1 ). This adjustment assumes that no more relevant thyroid cancers will be found in the 22 patients who have yet to undergo a thyroid surgical procedure. In addition, we counted the false negative GEC 0.64 cm papillary microcarcinoma as a true negative (technically the nodule was too small to biopsy and a large malignant lesion in the contralateral thyroid lobe drove our decisionmaking) and calculated the "best case" NPV for Afirma in our practice to be 89.6% (Table 1, Figure 1 ). If we assume that a minimum of two more relevant cancers would be uncovered at final pathologic evaluation (consistent with the cancer incidence in the already operated group) from the six as yet unoperated, suspicious GEC patients, our indeterminate FNA cancer prevalence rises to 36% and NPV falls to 88.3%
FNA Cellular Typology
Cytologically, 21 out of 58 (41%) of our indeterminate FNA's showed prominent Hurthle Cell populations.
In the Afirma GEC benign group, only 2 of 20 aspirates were noted by the TCP cytologists to contain significant Hurthle Cell (oncocytic) populations. The 18 nononcocytic FNA's included 16 AUS-FLUS lesions featuring follicular cells with mild atypia and 2 follicular neoplasms.
In contrast, in the Afirma GEC suspicious group, 19 out of 36 FNA's (53%) showed oncocytic predominance, with 12 Hurthle Cell dominant AUS-FLUS FNA's and 7 oncocytic follicular neoplasms (FN). Note that biopsies demonstrating Hurthle Cells in proximity to copious colloid and lymphocytes are not included in this discussion because Thyroid Cytopathology Partners interprets such FNA's as benign by Bethesda criteria.
Pathologic Correlates
36 surgeries were performed in our 58 patients with indeterminate FNA's (30 on GEC suspicious FNA patients, 5 on GEC benign FNA patients and 1 on a nondiagnostic GEC patient with insufficient RNA) ( Table 2 ). Ten oncocytic tumors were diagnosed at pathological evaluation (10/36 patients or 28%) including 7 Hurthle Cell adenomas, 2 multinodular goiters with Hurthle Cell metaplasia and 1 Hurthle Cell carcinoma (Table 2 -black fill, column 4). If we include the four contralateral thyroid lobe papillary microcarcinoma patients as false positive GEC's (Table 2 -red text), 9 of 13 false positive Afirma GEC patients (69%) were subsequently shown to have benign oncocytic pathology.
Thyroidectomy for patients with GEC suspicious oncocytic FNA's demonstrated a clinically relevant cancer on final pathology in 6 out of 17 surgeries (35%- Table 2 ). Once again, for the purposes of this analysis, we classified four contralateral thyroid lobe incidental papillary microcarcinomas as benign (i.e. not clinically significant), based on the fact that these lesions are routinely present in 6-36% of the healthy adult population (6, 7) . Using these classification criteria, a patient with a suspicious, oncocytic Afirma GEC result has roughly the same risk for harboring a clinically relevant thyroid cancer as a patient with a Bethesda 4 FNA result. Thus, for a patient with an oncocytic indeterminate FNA, Afirma GEC adds little information to enhance surgical decision making.
Thyroidectomy in patients with Afirma GEC suspicious, non-oncocytic, indeterminate FNA's produced a clinically relevant cancer on final pathology in 10 out 13 surgeries (77%- Table 2 ). Thus, the GEC suspicious, non-oncocytic, indeterminate FNA group appeared to be enriched with relevant thyroid cancer.
None of the five surgeries performed on patients with benign Afirma GEC's produced an oncocytic tumor; nor did the surgery on the patient with a nondiagnostic GEC (Table 2-blue and gray fill).
Discussion
In this paper, we analyze 27 successive months of Veracyte Afirma GEC use in our endocrine surgical practice and compare our GEC negative predictive value to that reported by Alexander et al in a much larger study involving 49 sites (mostly nonuniversity endocrinology practices) in 26 states over roughly the same duration. Like the participants in the Alexander et al study, we used Thyroid Cytopathology Partners, Inc. of Austin, Texas (TCP) for all cytologic interpretation, but unlike Alexander et al, we insisted on ethanol-fixation and air-drying of all our slides prior to transport. We did not use Thin-Prep liquid technology. Because the Pap technique requires wet staining, our slides were not examined with Papanicoau staining and this could have resulted in Bethesda classification differences.
In addition, we did not use 1-2 dedicated passes for Afirma GEC RNA collection, choosing instead to wash all our needle passes into FNA-protect solution after creating a slide for cytology. This technique did not appear to compromise the quality of the RNA specimens we provided, as only 2 of 58 Afirma GEC's (3%) were found to be RNA inadequate.
Indeterminate Group Cancer Prevalence and NPV
While the sex distribution and the average age of our Afirma patient population are similar to that described in the Alexander et al study, our cancer prevalence and final pathologic diagnosis distribution is different (4) . The cancer prevalence in our indeterminate group was at least 33% (probably closer to 36% once all Afirma GEC suspicious surgeries are complete), while the calculated cancer prevalence (with "suspicious for malignancy" cytology patients excluded) in the Alexander et al paper was almost 9% lower at 24.3%. The increased prevalence of thyroid cancer in our indeterminate group leads to a significant reduction in the negative predictive value of the Afirma GEC in our practice population. When cancer prevalence is plotted on a Cancer Prevalence vs NPV curve constructed from our practice sensitivity and specificity data (curve fitting algorithm supplied by Dr. Bryan McIver of the Moffitt Cancer Center), our calculated NPV falls to 89.6% (Table 1, Figure 1) . Thus, for our practice, more than one in ten of our benign GEC Afirma patients are likely to be misclassified. Although our current data is limited by the fact that 15 out of 20 patients in our Afirma GEC benign group have not undergone surgery, our experience still aptly demonstrates that the higher the prevalence of thyroid cancer in the tested population, the more likely that Afirma GEC will misclassify patients with malignant disease.
Oncocytic Case-Mix
In another divergence from the Alexander et al data, our indeterminate FNA patient group demonstrated a considerably higher percentage of oncocytic final pathologic diagnoses (28%) than did the multicenter trial (12%) (4) . Although the reason for our plethora of Hurthle Cell dominant final diagnoses is unclear, it is apparent that Afirma technology disproportionately distributes oncocytic indeterminate lesions into the suspicious GEC category (19 out of 21 oncocytic biopsies were classified as Afirma GEC suspicious) and that most of these Hurthle Cell lesions are benign on final pathologic evaluation (9 of 13 of the GEC false positive nodules contained dominant oncocytic cell populations on final pathology, including 7 Hurthle Cell adenomas and 2 multinodular goiters with Hurthle Cell metaplasia ( Table 2 ).
It is possible that the high concentration of oncocytic aspirates in our indeterminate specimens (21/58 or 36.2%) could have affected Afirma performance. 90% of our oncocytic aspirates (19 out of 21) were subsequently read as GEC "suspicious." Alexander et al (4) do not provide a breakdown of their indeterminate cytologies into oncocytic and non-oncocytic subsets, so we cannot directly compare our data to theirs. However, the fact that our prevalence of oncocytic final pathology was more than double theirs (28% vs 12%), suggests that that our indeterminate cytologic cell type distribution was likely different from theirs.
Historically, Hurthle Cell adenomas and carcinomas have been cytologically indistinguishable. Recent genomic deep sequencing studies provide evidence that Hurthle Cell carcinomas are genetically unique thyroid malignancies, distinct from papillary thyroid and follicular thyroid cancers (8) . Given the infrequency of Hurthle Cell malignancies, it is possible that the Afirma GEC was not adequately trained to differentiate benign from malignant oncocytic indeterminate FNA's. Although novel genetic Hurthle Cell markers have been described (8, 9) , no commercially available genetic test has been shown to reliably distinguish benign from malignant oncocytic tumors.
Summary
Our 27 month study of the Afirma Genetic Expression Classifier reveals that the negative predictive value for this thyroid surgery-preventing test diminishes considerably in populations where the indeterminate cytology group (excluding suspicious for DOI:10.4158/ EP13330.OR © 2013 AACE malignancy patients) contains more than 1 in 4 patients with thyroid cancer. Our study is limited by a relatively small sample size and by the fact that 22 of our patients with indeterminate FNA's (17 in the Afirma GEC benign group) have not undergone surgery. With such a limited sample size, a small number of misclassified cancers by Afirma testing can dramatically alter the sensitivity and specificity calculations for the GEC test and secondarily change negative predictive value calculations.
However, we encourage all thyroidologists and thyroid surgeons who use Afirma GEC technology to calculate or estimate practice-specific thyroid cancer prevalences in their indeterminate cytology patient groups. Using such cancer prevalence data, a practice-based re-estimation of the negative predictive value of a benign Afirma GEC test may prove to be informative. In endocrine surgical practices like ours, the negative predictive value of a benign Afirma GEC test may not be so robust as Alexander et al suggest (4) .
The problem of Hurthle Cell-rich thyroid aspirates that do not contain copious colloid or cellular evidence for chronic thyroiditis remains a vexing one. Commercially available genetic technology seems incapable of distinguishing benign from malignant Hurthle Cell lesions. Traditionally, oncocytic indeterminate cytology patients have been sent to surgery for diagnosis. Over our first 27 months of Afirma GEC use, 19 of 21 patients with indeterminate oncocytic cytologies were deemed suspicious by Afirma and sent for surgical diagnosis. Thus, in our practice, Afirma GEC added little information to the surgical selection process in patients with Hurthle Cell dominant cytopathology. Sensitivity and specificity calculations are in bold black. Negative predictive value (NPV) and positive predictive value (PPV) calculations are in italics.Two assumptions are depicted: The first in red italics assumes that the cancer prevalence in the 22 unoperated patients will be identical to that seen in the 35 operated patients-51.4%. The second assumption (best case scenario) assumes that there will be no further cancers detected in the 22 unoperated patients (black italics)-33% 
